Skip to main content
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Ticker · SHPH ISIN · US8256933024 US Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2025-03-31 Proxy Solicitation & In…
Country US United States of America
Listing US SHPH

About Shuttle Pharmaceuticals Holdings, Inc.

https://shuttlepharma.com/

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.

Recent filings

Filing Released Lang Actions
Proxy Solicitation & Information Statement 2025
Proxy Solicitation & Information Statement
2025-03-31 English
Board/Management Information 2025
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 30, 2025, by Shuttle Pharmaceuticals Holdings, Inc. It reports a material definitive agreement (an amended and restated employment agreement) and changes in senior management, including appointment of an interim CEO and a new Chief Scientific Officer. The content focuses on management changes and employment agreements rather than financial results or detailed financial statements. The document is not an annual or quarterly report, nor an earnings release. It is not a proxy statement or voting results announcement. The primary subject is the appointment and compensation of officers and restructuring of senior management. Therefore, the document fits best under Board/Management Information (MANG). The document length (6189 characters) and detailed description of management changes support this classification with high confidence.
2025-03-31 English
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports the entry into a material definitive agreement, specifically a consulting services agreement. The document includes details about the agreement, payment terms, and references the full agreement as an exhibit. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is a regulatory announcement of a material event rather than a full report or financial disclosure. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2025-03-25 English
Director's Dealing 2025
Director's Dealing
2025-03-22 English
Director's Dealing 2025
Director's Dealing
2025-03-22 English
Director's Dealing 2025
Director's Dealing
2025-03-22 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.